Bruce R. Korf, MD, PhD
Dr. Bruce R. Korf is Wayne H. and Sara Crews Finley Chair in medical genetics, Professor and Chair of the Department of Genetics, Director of the Heflin Center for Genomic Sciences at UAB, and Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine. He is a medical geneticist, pediatrician, and child neurologist, certified by the American Board of Medical Genetics (clinical genetics, clinical cytogenetics, clinical molecular genetics), American Board of Pediatrics, and American Board of Psychiatry and Neurology (child neurology).
His major research interests are the molecular diagnosis of genetic disorders and the natural history, genetics, and treatment of neurofibromatosis. He serves as Principal Investigator of the US Department of Defense–funded Neurofibromatosis Clinical Trials Consortium. Dr. Korf is President of the ACMG Foundation for Genetic and Genomic Medicine. He is co-author of Human Genetics and Genomics (4th edition), Medical Genetics at a Glance (3rd edition), Emery and Rimoin’s Principles and Practice of Medical Genetics (6th edition), and Current Protocols in Human Genetics.
Dr. Korf earned an PhD in genetics and cell biology from The Rockefeller University in New York and an MD degree from Cornell University Medical College in Boston. He completed a pediatrics residency at Children’s Hospital and a neurology residency at the Harvard-Longwood Neurology Training Program, all in Boston. He completed a genetics fellowship at the Harvard Medical School Genetics Training Program in Boston.
Darcy A. Krueger, MD, PhD
Dr. Darcy A. Krueger is Director of the Tuberous Sclerosis Clinic, Associate Professor of clinical pediatrics and neurology, and Associate Director of Research in Neurology at Cincinnati Children’s Hospital Medical Center (CCHMC) in Ohio.
Dr. Krueger is principal investigator, project leader, or major co-investigator for multiple TSC-focused clinical studies funded by the National Institutes of Health, including the TSC Autism Center of Excellence Network. Active preclinical, translational, and clinical research projects with both CCHMC and external collaborators are aimed at better understanding the underlying molecular mechanisms involved in tuberous sclerosis complex pathogenesis and treatment outcomes. He was the lead investigator in the clinical trial that used mechanistic target of rapamycin inhibitors to treat subependymal giant cell astrocytomas that led to the first FDA-approved treatment for tuberous sclerosis complex. He is a member of the senior advisory board of the Tuberous Sclerosis Complex Clinical Research Consortium.
Dr. Krueger earned a PhD in biochemistry and molecular biology and an MD degree from Saint Louis University and completed combined residencies in pediatrics, neurology, and child neurology at CCHMC and the University of Cincinnati College of Medicine.